Cryoablation Device PMA For Atrial Flutter To Be Financed With IPO Proceeds
This article was originally published in The Gray Sheet
Executive Summary
CryoCor will use approximately 35% of the $31.7 mil. it expects to net from an initial public offering to continue product development and complete a Phase II clinical trial of cryoablation to treat atrial flutter
You may also be interested in...
CryoCor European Recall Drops Sales As Firm Submits Atrial Flutter PMA
CryoCor does not believe a European recall of its Model 1200 cryoablation device will hamper efforts to secure PMA approval for the unit's successor, CryoBlator, in the U.S
CryoCor European Recall Drops Sales As Firm Submits Atrial Flutter PMA
CryoCor does not believe a European recall of its Model 1200 cryoablation device will hamper efforts to secure PMA approval for the unit's successor, CryoBlator, in the U.S
CryoCor submits PMA for atrial flutter
Safety and efficacy data from a 160-patient, 22-site clinical trial are submitted as final module to FDA for CryoBlater. The submission follows the opening of the firm's IPO in mid-July; funds from the public offering will be used to offset costs incurred from the trial. CryoCor also is preparing for an atrial fibrillation indication for its cryoablation device (1"The Gray Sheet" July 18, 2005, p. 8)...